Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FALCON: Modified FOLFIRINOX and Pentamidine in Advanced Pancreatic Cancer
NCT07829185Phase 1Not yet recruiting
- Sponsor
- University of Oklahoma
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pentamidine in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by University of Oklahoma. Primary endpoint: Adverse Events at 3 years. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
pentamidine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07829185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829185.